Hypofractionated Versus Conventionally Fractionated Radiotherapy for Initial Distant Metastases Nasopharyngeal Carcinoma

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 13, 2018

Primary Completion Date

June 10, 2020

Study Completion Date

April 10, 2022

Conditions
Nasopharyngeal Carcinoma
Interventions
RADIATION

Hypofraction radiation

"Hypofractionated dose IMRT: GTVnx 60Gy, GTVnd 60Gy, PTV1 50Gy and PTV2 45Gy in 25 fractions, 5 days/week.~Induced chemotherapy: Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles. After radiation, patients receive adjuvant chemotherapy Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles."

RADIATION

Standard dose IMRT

"Standard dose IMRT: GTVnx 69.69Gy, GTVnd 60-68Gy, PTV1 54.9Gy and PTV2 54Gy in 33 fractions, 5 days/week.~Induced chemotherapy: Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles. After radiation, patients receive adjuvant chemotherapy Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles."

Trial Locations (3)

Unknown

Guangxi Naxishan Hospital, Guilin

Linshan people's hospital, Linshan

Wuzhou Red Cross Hospital, Wuzhou

All Listed Sponsors
collaborator

Wuzhou Red Cross Hospital

OTHER

collaborator

Guangxi Naxishan Hospital

OTHER

collaborator

Nanning Monority Hospital

UNKNOWN

collaborator

Lingshan people's Hospital

UNKNOWN

lead

Wei Jiang

OTHER

NCT03598218 - Hypofractionated Versus Conventionally Fractionated Radiotherapy for Initial Distant Metastases Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter